| scholarly article | Q13442814 |
| P50 | author | David A Bush | Q57613723 |
| P2093 | author name string | Anthony L Zietman | |
| Jason A Efstathiou | |||
| John J Coen | |||
| Kyounghwa Bae | |||
| William U Shipley | |||
| Jerry D Slater | |||
| Carl J Rossi | |||
| B Rodney Jabola | |||
| Daphna Y Spiegel | |||
| Margie Lunt | |||
| Rafi Skowronski | |||
| P2860 | cites work | Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer | Q33336936 |
| Proton Radiation as Boost Therapy for Localized Prostatic Carcinoma | Q33895666 | ||
| Evaluation of survival data and two new rank order statistics arising in its consideration | Q34054360 | ||
| Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference | Q34541651 | ||
| Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. | Q34931729 | ||
| Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. | Q35617249 | ||
| The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry | Q35689357 | ||
| Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone | Q39379150 | ||
| Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma | Q41299562 | ||
| Biopsy after External Beam Radiation Therapy for Adenocarcinoma of the Prostate: Correlation with Original Histological Grade and Current Prostate Specific Antigen Levels | Q43515599 | ||
| Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial | Q44375182 | ||
| 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. | Q52957665 | ||
| Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. | Q55041226 | ||
| Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer | Q59650976 | ||
| Study duration for clinical trials with survival response and early stopping rule | Q68809187 | ||
| The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer | Q73090091 | ||
| Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel | Q73383408 | ||
| Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era | Q74816603 | ||
| Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer | Q77351947 | ||
| Conformal proton therapy for prostate carcinoma | Q77463835 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | radiation oncology | Q729267 |
| adaptive radiation therapy | Q180507 | ||
| adenocarcinoma | Q356033 | ||
| P304 | page(s) | 1106-1111 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09 | |
| P478 | volume | 28 |
| Q57480202 | A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526) |
| Q26738278 | A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer |
| Q58732160 | A novel prostate cancer immunotherapy using prostate-specific antigen peptides and skin test reagent as an adjuvant |
| Q90478128 | A prospective observational study to analyse the influence of bladder and rectal volume changes on prostate radiotherapy using IMRT |
| Q26800823 | A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer |
| Q43379694 | ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. |
| Q39456200 | ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. |
| Q39459690 | Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial |
| Q38981805 | Accumulated dose to the rectum, measured using dose-volume histograms and dose-surface maps, is different from planned dose in all patients treated with radiotherapy for prostate cancer |
| Q85173928 | Acute and Late Toxicity After Dose Escalation to 82 GyE Using Conformal Proton Radiation for Localized Prostate Cancer: Initial Report of American College of Radiology Phase II Study 03-12 |
| Q48141226 | Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer |
| Q46213032 | Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer - acute toxicity of 12C for PC. |
| Q57112442 | Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy |
| Q87215132 | Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease |
| Q34111603 | Androgen deprivation therapy for prostate cancer-review of indications in 2010 |
| Q86795201 | Androgen deprivation with radiotherapy: how long is long enough? |
| Q26863665 | Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review |
| Q47857314 | Approach to the Patient with High-Risk Prostate Cancer |
| Q47136587 | Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy |
| Q89688148 | Assessment of Polyethylene Glycol Hydrogel Spacer and Its Effect on Rectal Radiation Dose in Prostate Cancer Patients Receiving Proton Beam Radiation Therapy |
| Q26744485 | Big Data Analytics for Prostate Radiotherapy |
| Q42120277 | Biochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy |
| Q90092866 | Biochemical relapse free survival rate in patients with prostate cancer treated with external radiotherapy: outcomes obtained at the CMN Siglo XXI Hospital de Oncología, CMN 20 de Noviembre and Hospital General de México of the México City |
| Q60928058 | Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques |
| Q43440505 | CCAFU Recommendations 2013: Prostate cancer |
| Q36726123 | Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation? |
| Q36908059 | Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation? |
| Q37688674 | Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study. |
| Q38108208 | Charged particle therapy--optimization, challenges and future directions |
| Q89947390 | Clinical Outcomes of Dose-escalated Radiotherapy for Localised Prostate Cancer: A Single-institution Experience |
| Q38087711 | Clinical controversies: proton therapy for prostate cancer |
| Q37994609 | Clinical evidence of particle beam therapy (proton). |
| Q35992601 | Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. |
| Q39724232 | Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer |
| Q92073807 | Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions |
| Q38160244 | Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer |
| Q42562092 | Comment on "Proton beam and prostate cancer: An evolving debate" by Anthony Zietman [Rep. Pract. Oncol. Radiother. 2013;18:338-42] |
| Q94565363 | Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study |
| Q27011661 | Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group |
| Q37590695 | Comparative cost-effectiveness of focal and total salvage 125I brachytherapy for recurrent prostate cancer after primary radiotherapy |
| Q38804659 | Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant) |
| Q37965553 | Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions |
| Q33919002 | Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer |
| Q33626084 | Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis |
| Q57860471 | Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer |
| Q38848137 | Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer |
| Q48276400 | Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG. |
| Q57112410 | Contemporary role of postoperative radiotherapy for prostate cancer |
| Q47911220 | Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer |
| Q35947797 | Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer |
| Q34528219 | Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013". |
| Q48325008 | Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance |
| Q38095668 | Defining a dose-response relationship for prostate external beam radiotherapy |
| Q90479985 | Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study |
| Q60920436 | Definitive external-beam radiotherapy versus radical prostatectomy in clinically localized high-risk prostate cancer: a retrospective study |
| Q53120786 | Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets. |
| Q38109258 | Developments in external beam radiotherapy for prostate cancer |
| Q46844720 | Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. |
| Q36982057 | Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy |
| Q38152466 | Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer? |
| Q36925871 | Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer? |
| Q33679365 | Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes |
| Q64988730 | Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factor. |
| Q92281410 | Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data |
| Q38437266 | Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer |
| Q43478016 | Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy |
| Q34294112 | Drivers for change in the management of prostate cancer - guidelines and new treatment techniques |
| Q45905246 | Early Experiences of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Treatment in Localized Prostate Cancer. |
| Q57105892 | Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes |
| Q56519602 | Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial |
| Q49803982 | Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer |
| Q48187227 | Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer |
| Q33613683 | Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis |
| Q42474370 | Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger |
| Q42645856 | Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial |
| Q36653075 | Evaluation of Adherence to Quality Measures for Prostate Cancer Radiotherapy in the United States: Results from the Quality Research in Radiation Oncology (QRRO) Survey |
| Q26739738 | Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer |
| Q38135708 | Evolution of advanced technologies in prostate cancer radiotherapy |
| Q26744606 | Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies |
| Q26853068 | External beam radiotherapy for localized prostate cancer |
| Q39239309 | External beam radiotherapy in the treatment of prostate cancer |
| Q47794702 | Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients |
| Q39313355 | Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer |
| Q35131928 | Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience |
| Q35235550 | High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up |
| Q34024161 | High intensity focused ultrasound (HIFU) for prostate cancer: current clinical status, outcomes and future perspectives |
| Q31071413 | High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis |
| Q41375311 | High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial |
| Q34355194 | High-dose-rate brachytherapy boost for prostate cancer: rationale and technique |
| Q38026429 | High-intensity focused ultrasound and cryotherapy as salvage treatment in local radio-recurrent prostate cancer |
| Q35869811 | High-risk prostate cancer-classification and therapy |
| Q90430172 | Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes |
| Q36711751 | Hypofractionated external-beam radiotherapy for prostate cancer |
| Q42045691 | Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer |
| Q37547386 | Hypofractionated radiotherapy for localized prostate cancer |
| Q82966826 | Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial |
| Q38226822 | Hypofractionation in prostate cancer: radiobiological basis and clinical appliance. |
| Q38264783 | Hypofractioned radiotherapy in prostate cancer: is it the next step? |
| Q39504371 | Image-guided hypofractionated radiotherapy in low-risk prostate cancer patients |
| Q38100661 | Imaging treated prostate cancer |
| Q53138711 | Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. |
| Q41486881 | Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation. |
| Q53119315 | Impact of inter- and intrafraction deviations and residual set-up errors on PTV margins. Different alignment techniques in 3D conformal prostate cancer radiotherapy. |
| Q35985620 | Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer |
| Q39249070 | Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer |
| Q33725640 | Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer |
| Q38839208 | Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience |
| Q34268907 | Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer |
| Q41101008 | Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients. |
| Q51571128 | Interindividual registration and dose mapping for voxelwise population analysis of rectal toxicity in prostate cancer radiotherapy. |
| Q35123693 | Ion Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique |
| Q35582296 | Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment |
| Q57981842 | Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation |
| Q52716773 | LncRNA HULC mediates radioresistance via autophagy in prostate cancer cells. |
| Q40959972 | Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre |
| Q39030125 | Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel Disease |
| Q38937777 | Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer |
| Q43379657 | Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial |
| Q88682245 | Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer |
| Q41284078 | Long-term outcome of magnetic resonance spectroscopic image-directed dose escalation for prostate brachytherapy. |
| Q42373324 | Long-term outcomes in patients treated with proton therapy for localized prostate cancer. |
| Q50019892 | Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group |
| Q35530488 | Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. |
| Q44124651 | Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer |
| Q37243120 | Maintaining prostate contouring consistency following an educational intervention |
| Q92969050 | Management of radiation-induced proctitis |
| Q91436232 | Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer |
| Q57112499 | Moderate hypofractionation for prostate cancer |
| Q50079557 | Morbidity dynamics in proton-photon or photon radiation therapy for locally advanced prostate cancer |
| Q38914849 | Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy |
| Q38257845 | Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators |
| Q30386046 | Near-infrared fluorescence imaging platform for quantifying in vivo nanoparticle diffusion from drug loaded implants. |
| Q57885705 | New types of radiotherapy improve cancer outcome but at what cost? |
| Q47287536 | Optimizing androgen deprivation therapy with radiation therapy for aggressive localized and locally advanced prostate cancer |
| Q35040471 | Outcomes and predictors of localized or locally-advanced prostate cancer treated by radiotherapy in Indonesia |
| Q90397468 | Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database |
| Q55100642 | Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer. |
| Q47420362 | Outcomes of Asian patients with localized prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: A single institution experience |
| Q36520539 | Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? |
| Q37706714 | PAFR selectively mediates radioresistance and irradiation-induced autophagy suppression in prostate cancer cells |
| Q42207559 | PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. |
| Q91713571 | Particle therapy for prostate cancer: The past, present and future |
| Q38357630 | Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis |
| Q38954114 | Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database |
| Q37139334 | Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer |
| Q38837262 | Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes |
| Q37888666 | Pharmacotherapeutic management of locally advanced prostate cancer: current status |
| Q90230404 | Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer |
| Q35111775 | Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer |
| Q33613649 | Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks |
| Q30454149 | Point/counterpoint. High intensity focused ultrasound may be superior to radiation therapy for the treatment of early stage prostate cancer |
| Q37960204 | Postprostatectomy radiation therapy: an evidence-based review |
| Q38252429 | Progress and controversies: Radiation therapy for prostate cancer |
| Q85173922 | Prolongation of Total Treatment Time Because of Infrequently Missed Days of Treatment Is Not Associated With Inferior Biochemical Outcome After Dose-Escalated Radiation Therapy for Prostate Cancer |
| Q34124263 | Promise and pitfalls of heavy-particle therapy |
| Q41608117 | Propensity Score Matched Comparison of Intensity Modulated Radiation Therapy vs Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Survival Analysis from the National Cancer Database |
| Q42165844 | Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer |
| Q33415382 | Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer |
| Q37578562 | Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know? |
| Q26749961 | Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine |
| Q36555616 | Prostate cancer brachytherapy: guidelines overview |
| Q27022847 | Prostate cancer: ESMO Consensus Conference Guidelines 2012 |
| Q85171998 | Prostate cancer: Patient-reported functional outcomes with radiation therapy |
| Q46936242 | Prostate cancer: Proton therapy--revolutionary advance or diminishing returns? |
| Q34946192 | Prostate gland lengths and iceball dimensions predict micturition functional outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer |
| Q38543109 | Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions |
| Q36563924 | Proton Beams Inhibit Proliferation of Breast Cancer Cells by Altering DNA Methylation Status |
| Q38177807 | Proton beam and prostate cancer: An evolving debate |
| Q38095001 | Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified? |
| Q91487219 | Proton beam therapy after radical prostatectomy |
| Q38088468 | Proton beam therapy and localised prostate cancer: current status and controversies |
| Q42697014 | Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts. |
| Q28070150 | Proton beam therapy: clinical utility and current status in prostate cancer |
| Q38786895 | Proton therapy - Present and future |
| Q28072657 | Proton therapy for early stage prostate cancer: is there a case? |
| Q90346232 | Proton therapy for prostate cancer: A review of the rationale, evidence, and current state |
| Q92987333 | Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care |
| Q26767399 | Protons, Photons, and the Prostate - Is There Emerging Evidence in the Ongoing Discussion on Particle Therapy for the Treatment of Prostate Cancer? |
| Q89572879 | Quality indicators of clinical cancer care for prostate cancer: a population-based study in southern Switzerland |
| Q34111590 | Radiation Therapy in Prostate Cancer: A Risk-Adapted Strategy |
| Q39448990 | Radiation proctitis: current strategies in management |
| Q36241918 | Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted". |
| Q35992830 | Radiation treatment for patients with intermediate-risk prostate cancer |
| Q45741346 | Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. |
| Q37176612 | Radiotherapy and Hormone Treatment in Prostate Cancer |
| Q37081939 | Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up |
| Q57284584 | Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer |
| Q63966222 | Recommandations en Onco-Urologie 2010 : Cancer de la prostate |
| Q30428790 | Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada? |
| Q37725623 | Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis. |
| Q39156783 | Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways |
| Q28081451 | Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy? |
| Q37283766 | Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer |
| Q39422186 | Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: a Literature Review |
| Q34627488 | Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications |
| Q30857429 | Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry |
| Q34355171 | Salvage low-dose-rate (125)I partial prostate brachytherapy after dose-escalated external beam radiotherapy |
| Q41864424 | Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration |
| Q41357271 | Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria |
| Q38757854 | Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone |
| Q38015028 | Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? |
| Q33993238 | Significance of image guidance to clinical outcomes for localized prostate cancer |
| Q60928051 | SpaceOAR to improve dosimetric outcomes for monotherapy high-dose-rate prostate implantation in a patient with ulcerative colitis |
| Q48085035 | Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer |
| Q64324920 | Stereotactic Body Radiotherapy for Primary Prostate Cancer |
| Q38268325 | Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)). |
| Q90681613 | Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials |
| Q55261881 | Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial. |
| Q42702939 | Stereotactic radiotherapy for prostate cancer: A review and future directions |
| Q33919686 | Stereotactic radiotherapy of the prostate: fractionation and utilization in the United States |
| Q38382252 | Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial |
| Q37324126 | Systematic review of hypofractionated radiation therapy for prostate cancer |
| Q92358102 | Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy |
| Q42077442 | Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo |
| Q89971939 | Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer |
| Q37195789 | The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups |
| Q61807677 | The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States |
| Q46765601 | The German S3 guideline prostate cancer: aspects for the radiation oncologist |
| Q26770254 | The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial Lesions |
| Q39200876 | The Role of Hypofractionated Radiotherapy in Prostate Cancer |
| Q38035919 | The current role of high-intensity focused ultrasound for the management of radiation-recurrent prostate cancer. |
| Q35166901 | The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer. |
| Q42506349 | The effects of motion on the dose distribution of proton radiotherapy for prostate cancer |
| Q36557988 | The importance of local control in high-risk locally advanced prostate cancer |
| Q36338835 | The management of high-risk, locally advanced, prostate cancer radiation therapy |
| Q35531022 | The physics of proton therapy |
| Q35605924 | The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation |
| Q38910225 | The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer |
| Q57112397 | The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer |
| Q38673916 | The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update |
| Q92534692 | Three Discipline Collaborative Radiation Therapy (3DCRT) Special Debate: I would treat prostate cancer with proton therapy |
| Q37506977 | Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment |
| Q36141341 | Tissue biomarkers for prostate cancer radiation therapy |
| Q42116803 | Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond |
| Q37586877 | Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer |
| Q43825679 | Translational uroradio-oncology |
| Q37134562 | Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California |
| Q40959922 | Treatment outcomes with hypofractionated high-dose radiation therapy for prostate cancer |
| Q92354835 | Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers |
| Q37852580 | Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity |
| Q42709732 | Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials |
| Q85485507 | Urological cancer. The benefits of intermittent androgen-deprivation therapy |
| Q37342181 | Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. |
| Q38721165 | Voxel-based population analysis for correlating local dose and rectal toxicity in prostate cancer radiotherapy. |
| Q40400351 | Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. |
| Q38412788 | What is the best way to radiate the prostate in 2016? |
| Q84484191 | [Benefit assessment by the Federal Joint Committee: assessment of treatment strategies for low risk prostate cancer] |
| Q52719200 | β‑catenin nuclear translocation induced by HIF‑1α overexpression leads to the radioresistance of prostate cancer. |
Search more.